Dyslipidemia
📧 Sign up to get email alerts when something new happens for Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-12-30Clinical Trial Update: Gamification to Increase Mobility in the Hospital [NA]
The clinical trial NCT04300764 evaluating gamification to increase mobility in hospitalized patients has been withdrawn. The sponsor is the …
-
CLINICAL_TRIALS withdrawal · 2025-03-06Clinical Trial Update: Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
A clinical trial evaluating how cholesterol levels affect long-term patency of coronary artery bypass grafts has been withdrawn; the study i…
-
CLINICAL_TRIALS withdrawal · 2022-02-18Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406) [Phase 4]
Phase 4 trial evaluating Vytorin vs standard statin therapy for dyslipidemia was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-05-10Clinical Trial Update: Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia [Phase 3]
Phase 3 trial comparing NK-104-CR and Livalo IR in primary hyperlipidemia or mixed dyslipidemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-05-10Clinical Trial Update: Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia [Phase 3]
Phase 3 trial NK-104-CR for primary hyperlipidemia or mixed dyslipidemia was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2021-02-24Clinical Trial Update: Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia. [Phase 3]
Phase 3 trial of a fixed-dose combination of valsartan and rosuvastatin was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-12-02Clinical Trial Update: Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects [Phase 3]
Pfizer has withdrawn the Phase 3 trial evaluating bococizumab for lipid lowering in Asian subjects with primary hyperlipidemia or mixed dysl…
-
CLINICAL_TRIALS withdrawal · 2016-09-27Clinical Trial Update: Genetic Influence on Statin Pharmacodynamics
A clinical trial investigating genetic influence on statin pharmacodynamics was withdrawn from the registry.
-
CLINICAL_TRIALS withdrawal · 2016-05-24Clinical Trial Update: A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. [Phase 4]
A Phase 4 trial evaluating azilsartan on coronary artery plaque in patients with essential hypertension, stable angina, and dyslipidemia has…
-
CLINICAL_TRIALS withdrawal · 2016-05-19Clinical Trial Update: The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study [NA]
A clinical trial investigating artichoke leaf extract for lowering blood cholesterol has been withdrawn, with the study no longer active for…
-
CLINICAL_TRIALS withdrawal · 2015-06-12Clinical Trial Update: Dyslipidemia in Type 2 Diabetes (0767-034) [Phase 3]
A Phase 3 clinical trial evaluating dyslipidemia in adults with type 2 diabetes (NCT00547274) was terminated.
-
CLINICAL_TRIALS withdrawal · 2015-04-23Clinical Trial Update: Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia [Phase 1]
Phase 1 multiple-dose safety study of the investigational drug RN316 for hypercholesterolemia/dyslipidemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-09Clinical Trial Update: Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) [Phase 3]
A Phase 3 trial of extended-release niacin added on with laropiprant for dyslipidemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-07-24Clinical Trial Update: Observational Study To Evaluate Statins Patterns Of Use In Spain
An observational study evaluating statin usage in Spain has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2011-04-12Clinical Trial Update: Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
AstraZeneca-sponsored clinical trial on dyslipidemia treatment in Thailand investigating cardiovascular outcomes has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2010-12-10Clinical Trial Update: Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors [Phase 3]
A Phase 3 trial evaluating the impact of rimonabant on regression of asymptomatic cardiovascular damage was terminated.
-
CLINICAL_TRIALS withdrawal · 2009-07-20Clinical Trial Update: Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS) [Phase 3]
Phase 3 VENUS trial of rimonabant in Japanese obese patients with dyslipidemia has been terminated.